Decrease in cognitive performance and increase of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with higher doses of antipsychotics in women with schizophrenia: a cross-sectional study

BMC Psychiatry. 2023 Aug 2;23(1):558. doi: 10.1186/s12888-023-05050-x.

Abstract

Background: We explored the relationship between symptoms, cognitive performance, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) (three markers of inflammation), and antipsychotic dose (in chlorpromazine units) in male and female patients with schizophrenia.

Methods: We conducted a cross-sectional analysis in patients with schizophrenia of the complete blood count and the results of neuropsychological testing, using the Welch t-test to compare groups and the Pearson test for correlations.

Results: We found that the NLR and the PLR are higher among women with schizophrenia when compared with men. In women, the NLR and the PLR correlate positively with antipsychotic drug dose and inversely with a working memory test (Direct Digit Span). Higher doses of antipsychotics are associated with worse working and semantic memory and mental flexibility in the women in our sample.

Conclusion: Higher doses of antipsychotics were associated with worse working and semantic memory and mental flexibility in women with schizophrenia. No such correlations were present in men, suggesting that, in female patients, cognitive performance deteriorates as the antipsychotic dose is increased, a finding that could be mediated by inflammatory mechanisms, given the demonstrated relationship to biomarkers of inflammation - e.g., the NLR and the PLR.

Trial registration: NCT03788759 (ClinicalTrials.gov).

Keywords: Antipsychotics; Executive function; Inflammation; Neuropsychological tests; Neutrophil-to-lymphocyte ratio; Schizophrenia.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antipsychotic Agents* / therapeutic use
  • Cognition
  • Cross-Sectional Studies
  • Female
  • Humans
  • Inflammation
  • Lymphocytes
  • Male
  • Neutrophils
  • Schizophrenia* / drug therapy

Substances

  • Antipsychotic Agents

Associated data

  • ClinicalTrials.gov/NCT03788759